Bristol-Myers Squibb Company(BMY)NASDAQ
Company Profile & Information
Company Profile
Business overview, scale, and footprint
Business Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.
In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer.
The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Insider Transactions
Open-market activity and option exercises
Insider Activity Summary
Insider trading activity for Bristol-Myers Squibb Company (BMY) over the last 3 months consists of 55 total transactions. Among these, company executives and board members conducted 55 buys (totaling 852,223 shares) and 0 sells (totaling 0 shares). This activity resulted in a net change of 852,223 shares, reflecting net buying interest with an estimated net acquisitions value of $34.16M.
55 insider transactions found. Showing 10 of 55 transactions.
| Insider Name | Relation to Company | Shares Changed | Price | Transaction Date |
|---|---|---|---|---|
| HALLER JULIA A | Director | 20,460 | $1.10 | Jun 15, 2026 |
| SHORT BARTIE WENDY | Officer | 8,040 | $N/A | Jun 3, 2026 |
| LENKOWSKY ADAM | Officer | 1,373 | $N/A | May 1, 2026 |
| ELKINS DAVID VINCENT | Chief Financial Officer | 30,000 | $1.85 | Apr 1, 2026 |
| SHANAHAN KARIN | Officer | 3,307 | $N/A | Apr 1, 2026 |
| MEYERS GREGORY SCOTT | Chief Technology Officer | 25,892 | $N/A | Mar 10, 2026 |
| SHANAHAN KARIN | Officer | 25,501 | $N/A | Mar 10, 2026 |
| LENKOWSKY ADAM | Officer | 24,071 | $N/A | Mar 10, 2026 |
| GALLMAN CARI | General Counsel | 6,980 | $N/A | Mar 10, 2026 |
| HOCH LYNELLE BAUMGARDNER | Officer | 8,192 | $N/A | Mar 10, 2026 |